Hologic, Inc. (NASDAQ:HOLX) will be announcing its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of $0.49 per share for the quarter.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $39.06 on Tuesday. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.65 and a current ratio of 0.85. The firm has a market capitalization of $11,095.53, a PE ratio of 19.39, a price-to-earnings-growth ratio of 1.74 and a beta of 0.93.

In related news, Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence M. Levy sold 7,138 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The disclosure for this sale can be found here. Insiders sold 23,873 shares of company stock worth $898,754 over the last three months. 0.79% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/hologic-inc-holx-scheduled-to-post-quarterly-earnings-on-wednesday/1684261.html.

HOLX has been the topic of a number of recent research reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research note on Friday, July 14th. Deutsche Bank AG reduced their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) cut Hologic from a “conviction-buy” rating to a “buy” rating and reduced their price objective for the company from $48.00 to $47.00 in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $47.77.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.